http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Recurrent <i>ETNK1</i> mutations in atypical chronic myeloid leukemia
Gambacorti-Passerini, Carlo B.,Donadoni, Carla,Parmiani, Andrea,Pirola, Alessandra,Redaelli, Sara,Signore, Giovanni,Piazza, Vincenzo,Malcovati, Luca,Fontana, Diletta,Spinelli, Roberta,Magistroni, Vera American Society of Hematology 2015 Blood Vol.125 No.3
<P>Despite the recent identification of recurrent <I>SETBP1</I> mutations in atypical chronic myeloid leukemia (aCML), a complete description of the somatic lesions responsible for the onset of this disorder is still lacking. To find additional somatic abnormalities in aCML, we performed whole-exome sequencing on 15 aCML cases. In 2 cases (13.3%), we identified somatic missense mutations in the <I>ETNK1</I> gene. Targeted resequencing on 515 hematological clonal disorders revealed the presence of <I>ETNK1</I> variants in 6 (8.8%) of 68 aCML and 2 (2.6%) of 77 chronic myelomonocytic leukemia samples. These mutations clustered in a small region of the kinase domain, encoding for H243Y and N244S (1/8 H243Y; 7/8 N244S). They were all heterozygous and present in the dominant clone. The intracellular phosphoethanolamine/phosphocholine ratio was, on average, 5.2-fold lower in ETNK1-mutated samples (<I>P</I> < .05). Similar results were obtained using myeloid TF1 cells transduced with ETNK1 wild type, ETNK1-N244S, and ETNK1-H243Y, where the intracellular phosphoethanolamine/phosphocholine ratio was significantly lower in ETNK1-N244S (0.76 ± 0.07) and ETNK1-H243Y (0.37 ± 0.02) than in ETNK1-WT (1.37 ± 0.32; <I>P</I> = .01 and <I>P</I> = .0008, respectively), suggesting that <I>ETNK1</I> mutations may inhibit the catalytic activity of the enzyme. In summary, our study shows for the first time the evidence of recurrent somatic <I>ETNK1</I> mutations in the context of myeloproliferative/myelodysplastic disorders.</P>